MX2022012544A - Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. - Google Patents
Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar.Info
- Publication number
- MX2022012544A MX2022012544A MX2022012544A MX2022012544A MX2022012544A MX 2022012544 A MX2022012544 A MX 2022012544A MX 2022012544 A MX2022012544 A MX 2022012544A MX 2022012544 A MX2022012544 A MX 2022012544A MX 2022012544 A MX2022012544 A MX 2022012544A
- Authority
- MX
- Mexico
- Prior art keywords
- mir
- inhibitor
- pulmonary fibrosis
- treatment
- macrophages
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 108091062762 miR-21 stem-loop Proteins 0.000 title abstract 5
- 108091041631 miR-21-1 stem-loop Proteins 0.000 title abstract 5
- 108091044442 miR-21-2 stem-loop Proteins 0.000 title abstract 5
- 210000002540 macrophage Anatomy 0.000 title abstract 3
- 208000005069 pulmonary fibrosis Diseases 0.000 title abstract 3
- 208000019693 Lung disease Diseases 0.000 abstract 2
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona con una composición para utilizarse en el tratamiento de la fibrosis pulmonar de un sujeto, donde la composición comprende un inhibidor de miR-21 y un resto que libera el inhibidor de miR-21 a un macrófago. Además, la composición puede administrarse por medio de una administración pulmonar. En aspectos particulares, el sujeto a ser tratado padece fibrosis pulmonar y tiene además una enfermedad o trastorno pulmonar, donde la enfermedad o trastorno pulmonar puede ser una enfermedad por coronavirus. Además, la invención se relaciona con una composición, donde la composición comprende un inhibidor de miR-21 y un resto que libera el inhibidor de miR-21 a un macrófago pulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20169160 | 2020-04-09 | ||
PCT/EP2021/059360 WO2021205032A1 (en) | 2020-04-09 | 2021-04-09 | Targeted delivery of an inhibitor of mir-21 to macrophages for the treatment of pulmonary fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022012544A true MX2022012544A (es) | 2022-11-07 |
Family
ID=70285565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022012544A MX2022012544A (es) | 2020-04-09 | 2021-04-09 | Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230287413A1 (es) |
EP (1) | EP4133075A1 (es) |
JP (1) | JP2023521785A (es) |
KR (1) | KR20230008741A (es) |
CN (1) | CN115698289A (es) |
AU (1) | AU2021252156A1 (es) |
BR (1) | BR112022017215A2 (es) |
CA (1) | CA3168954A1 (es) |
IL (1) | IL297060A (es) |
MX (1) | MX2022012544A (es) |
WO (1) | WO2021205032A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024096516A1 (ko) * | 2022-11-02 | 2024-05-10 | 이화여자대학교 산학협력단 | 핵산 약물의 경폐전달을 위한 지질나노입자 제형 및 이의 활용 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
ATE419355T1 (de) | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
CA2385743A1 (en) | 1999-09-28 | 2001-04-05 | Universitat Zurich | Factors having prion-binding activity in serum and plasma and agents to detect transmissible spongiform encephalopathitis |
HUP0300369A2 (hu) | 2000-04-11 | 2003-06-28 | Genentech, Inc. | Többértékű antitestek és alkalmazásuk |
AU2014256406A1 (en) * | 2008-02-27 | 2014-11-20 | Julius Maximilians-Universitat Wurzburg | MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes |
EP2096171A1 (en) | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
KR102118429B1 (ko) * | 2012-04-25 | 2020-06-03 | 사노피 | 마이크로rna 화합물 및 mir-21 활성 조절 방법 |
US9994846B2 (en) * | 2013-10-25 | 2018-06-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
US9833416B2 (en) * | 2014-04-04 | 2017-12-05 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
US11085071B2 (en) * | 2017-02-01 | 2021-08-10 | Spot Biosystems Ltd. | Highly stable and specific molecular beacons encapsulated in cationic lipoplex nanoparticles and application thereof |
-
2021
- 2021-04-09 CA CA3168954A patent/CA3168954A1/en active Pending
- 2021-04-09 BR BR112022017215A patent/BR112022017215A2/pt unknown
- 2021-04-09 US US17/995,722 patent/US20230287413A1/en active Pending
- 2021-04-09 WO PCT/EP2021/059360 patent/WO2021205032A1/en unknown
- 2021-04-09 AU AU2021252156A patent/AU2021252156A1/en active Pending
- 2021-04-09 EP EP21716768.3A patent/EP4133075A1/en active Pending
- 2021-04-09 KR KR1020227039237A patent/KR20230008741A/ko active Search and Examination
- 2021-04-09 IL IL297060A patent/IL297060A/en unknown
- 2021-04-09 CN CN202180027447.6A patent/CN115698289A/zh active Pending
- 2021-04-09 JP JP2022561618A patent/JP2023521785A/ja active Pending
- 2021-04-09 MX MX2022012544A patent/MX2022012544A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230287413A1 (en) | 2023-09-14 |
WO2021205032A1 (en) | 2021-10-14 |
BR112022017215A2 (pt) | 2022-10-18 |
KR20230008741A (ko) | 2023-01-16 |
CA3168954A1 (en) | 2021-10-14 |
EP4133075A1 (en) | 2023-02-15 |
JP2023521785A (ja) | 2023-05-25 |
IL297060A (en) | 2022-12-01 |
CN115698289A (zh) | 2023-02-03 |
AU2021252156A1 (en) | 2022-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500088A1 (en) | Substituted tricyclics and method of use | |
MX2019012884A (es) | Terapia de combinacion. | |
MX2019006938A (es) | Metodos y composiciones para trataminto de hipertension pulmonar y otros trastornos del pulmon. | |
MY194313A (en) | Substituted chromanes and method of use | |
MX2021009199A (es) | Conjugado de farmaco de dos ligandos y uso del mismo. | |
MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
MX2010009623A (es) | Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
WO2010123569A3 (en) | Immunonanotherapeutics providing a th1-biased response | |
MX2015012397A (es) | Composiciones y metodos basados en anticuerpos neutralizados suministrados intranasalmente para eficacia terapeutica aumentada. | |
MX2010009625A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40. | |
EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
MX339555B (es) | Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento. | |
GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
MX2022014786A (es) | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. | |
NZ744323A (en) | Compositions comprising 15-hepe and methods of using the same | |
MX2016002302A (es) | Composiciones y metodos terapeuticos para la regresion acelerada de placa. | |
MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
MX2022012544A (es) | Liberacion dirigida de un inhibidor de mir-21 a macrofagos para el tratamiento de la fibrosis pulmonar. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. |